News

Kanagawa, Japan, 18th, December 2022 – FIMECS, Inc. (CEO: Yusuke Tominari, Ph.D., “FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D. Co-founder, CEO of FIMECS received the “Outstanding Leadership Award” at the Health 2.0 Conference (16th-18th December 2022, Dubai, UAE).

Health 2.0, started in California in 2007, is the global conference introducing the latest technologies and advanced solutions in the medical and health sector. The Health 2.0 Conference is annually held at the Dubai (UAE) and Las Vegas (USA), which is well known as a premier event wherein the global healthcare community including more than 1000 participants will convene to discuss ways and means to improve the entire health and wellness ecosystem.

The event serves as a common ground, for professionals from the pharma, healthcare, medical devices, and biotech sectors to discuss, brainstorm and explore new perspectives and ideas. It covers a wide range of tracks, from digital health, patient safety, drug and vaccine development, hospital management, AI in healthcare and much, much more.

The Outstanding Leadership Award, which Yusuke received, is awarded to those who are recognized for their contributions to the advancement of knowledge and technological innovation by leading the healthcare industry, based on a comprehensive evaluation of five criteria: Leader’s Reputation, Educational Background, Professional Experience, Creative Thinking, and Decisive Leadership, by the Health 2.0 Assessment Committee.

“I’m great honored to receive the Outstanding Leadership Award from world-renowned Health 2.0. I believe that our enthusiasm to deliver game-changing medicines to the patients has been highly praised.” said Awardee, Yusuke Tominari, Ph.D., Co-founder, CEO of FIMECS. “I believe that the award is a recognition of the leadership for founding FIMECS, establishing of a foundation of the company supported by FIMECS’ co-founder, CSO, Kanae Gamo, Ph.D., in addition, we have kept trying “Drugging Undruggable Targets” based on the new modality Targeted Protein Degradation, together with our employees. We will continue to work as a team to expand our business worldwide, and to promote our research to discover the innovative medicines.”

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
TEL: +81-466-96-0261
E-mail: info@fimecs.com